Receive Our Newsletter

Hemophilia Bleeding Disorder Industry News
Industry News

Sangamo BioSciences Announces New Gene Therapy Clinical Development Program

Note: The below is an edited version of an article originally published on PR Newswire. The original release can be read in its entirety here. Sangamo BioSciences, Inc. announced the presentation of preclinical data that supports the clinical development of its new proprietary gene therapy for the treatment of hemophilia A. This new therapeutic comprises an adeno-associated […]

Industry News

uniQure Presents Updated Clinical Data in Patients with Severe Hemophilia B

Note: The below is an edited version of an article originally published on Globe Newswire. The original release can be read in its entirety here. uniQure N.V. yesterday announced updated clinical data from its ongoing Phase I/II trial of AMT-060, its proprietary, investigational gene therapy, in patients with severe hemophilia B.  The updated data show that […]

Industry News

CSL Behring Presents Phase 3 Data about Afstyla for Hemophilia A

Note: The below is an edited version of an article originally published on PR Newswire. The original release can be read in it’s entirety here. CSL Behring today presented data from a Phase III pivotal study of Afstyla [Antihemophilic Factor (Recombinant), Single Chain] in hemophilia A patients less than 12 years of age at the XXXII International Congress […]

medical_news_600x600

Voluntary Withdrawals of Helixate FS & Kogenate FS

As part of HFA’s ongoing mission to assist and advocate for the bleeding disorders community, this medical news is being issued to keep you informed about product safety. About These Withdrawals CSL Behring is initiating a voluntarily recall of two lots of its hemophilia A drug Helixate FS containing active ingredient manufactured before November 2015. […]

Industry News

Adynovate Phase 3 Efficacy and Safety Data in Children to be Presented

Note: The below is an edited version of an article originally published on PR Newswire. The original release can be read in it’s entirety here. _________________________________________________________________________________________ Shire will present additional data on the clinical experience of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended half-life recombinant Factor VIII (rFVIII) replacement for hemophilia A, during the International […]

Industry News

CSL Behring Presents Phase III Data for IDELVION for Hemophilia B

Note: The below is an edited version of an article originally published on Yahoo Finance. The original release can be read in it’s entirety here. _________________________________________________________________________________________ CSL Behring announced new data today from its Phase III PROLONG-9FP clinical development program evaluating IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company’s long-acting recombinant albumin fusion protein […]

Industry News

Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran

Note: The below is an edited version of an article originally published on StreetInsider.com. The original release can be read in it’s entirety here. _________________________________________________________________________________________ Alnylam Pharmaceuticals, Inc. announced today new positive results from its ongoing Phase 1 study with Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B and […]

Industry News

Novo Nordisk Announces New Data on Psychosocial Impact of People Living with Hemophilia B

Note: The below is an edited version of a press release by Novo Nordisk. The original release can be read in it’s entirety here.  Novo Nordisk today announced the first results from the Bridging Hemophilia B Experiences, Results and Opportunities into Solutions (B-HERO-S) study, which found that many adults and children living with even mild or […]

Industry News

Spark Therapeutics and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B

Note: The below is an edited version of a press release by Spark Therapeutics. The original release can be read in it’s entirety here. Spark Therapeutics and Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to SPK-9001, the lead investigational candidate in the companies’ SPK-FIX program, in development for the treatment of hemophilia B. SPK-9001, a […]

Industry News

Kedrion Announces Voluntary, Temporary Hold on Koate-DVI

Kedrion Biopharma provided the following announcement today: Koate®-DVI Summer Supply Statement Kedrion Biopharma has placed a voluntary, temporary hold on further shipments of Koate-DVI until approximately the September timeframe. The company is working to restore supplies of Koate-DVI as soon as possible so that it can be made available to patients who require it. This is being […]

Page 8 of 27« FirstPrevious45678910111213NextLast »

Assisting and Advocating for the Bleeding Disorders Community